company background image
500660 logo

GlaxoSmithKline Pharmaceuticals BSE:500660 Stock Report

Last Price

₹2.70k

Market Cap

₹445.1b

7D

9.1%

1Y

92.6%

Updated

13 Jun, 2024

Data

Company Financials +

GlaxoSmithKline Pharmaceuticals Limited

BSE:500660 Stock Report

Market Cap: ₹445.1b

500660 Stock Overview

Manufactures, distributes, and trades in pharmaceuticals in India and internationally.

500660 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends3/6

GlaxoSmithKline Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GlaxoSmithKline Pharmaceuticals
Historical stock prices
Current Share Price₹2,699.10
52 Week High₹2,666.85
52 Week Low₹1,376.50
Beta0.22
1 Month Change35.01%
3 Month Change40.27%
1 Year Change92.56%
3 Year Change74.90%
5 Year Change116.25%
Change since IPO2,194.67%

Recent News & Updates

Recent updates

Shareholder Returns

500660IN PharmaceuticalsIN Market
7D9.1%3.3%5.1%
1Y92.6%56.1%43.8%

Return vs Industry: 500660 exceeded the Indian Pharmaceuticals industry which returned 56.1% over the past year.

Return vs Market: 500660 exceeded the Indian Market which returned 43.8% over the past year.

Price Volatility

Is 500660's price volatile compared to industry and market?
500660 volatility
500660 Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement6.7%
10% most volatile stocks in IN Market9.8%
10% least volatile stocks in IN Market4.5%

Stable Share Price: 500660's share price has been volatile over the past 3 months.

Volatility Over Time: 500660's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19243,211Bhushan Akshikarindia-pharma.gsk.com

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease.

GlaxoSmithKline Pharmaceuticals Limited Fundamentals Summary

How do GlaxoSmithKline Pharmaceuticals's earnings and revenue compare to its market cap?
500660 fundamental statistics
Market cap₹445.14b
Earnings (TTM)₹5.90b
Revenue (TTM)₹34.54b

77.5x

P/E Ratio

13.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
500660 income statement (TTM)
Revenue₹34.54b
Cost of Revenue₹13.55b
Gross Profit₹20.99b
Other Expenses₹15.09b
Earnings₹5.90b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)34.83
Gross Margin60.76%
Net Profit Margin17.08%
Debt/Equity Ratio0%

How did 500660 perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

92%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.